CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 70 enrolled
Drug / intervention
PF-07321332 Dose 1 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04756531
NCT04756531Phase 1Completed
CompareCT.gov

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 07321332 IN HEALTHY ADULT PARTICIPANTS

Pfizer·interventional·Posted Feb 16, 2021·Updated Oct 15, 2024

In Brief

A Phase 1 clinical trial evaluating PF-07321332 Dose 1, PF-07321332 Dose 2, and 4 other interventions for Healthy Participants. Completed, enrolled 70 participants across 2 sites in 2 countries.

Detailed Summary

A Phase 1, double blind, sponsor open, single and multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of PF-07321332 in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesBelgium, United States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedFeb 16, 2021
Enrollment StartFeb 11, 2021
Primary CompletionSep 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.4 years ago

Interventions

PF-07321332 Dose 1drug

PF-07321332 Dose 1 or Placebo

PF-07321332 Dose 2drug

PF-07321332 Dose 2 or Placebo

PF-07321332 Dose 3drug

PF-07321332 Dose 3 or Placebo

PF-07321332 Dose 4drug

PF-07321332 Dose 4 or Placebo

PF-07321332 Dose 5drug

PF-07321332 Dose 5 or Placebo

PF-07321332 Dose 4 or Placebo (Fed)drug

PF-07321332 Dose 5 or Placebo with high fat meal